Associated comorbidities in psoriasis and inflammatory bowel disease

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 5, 2012, Pages 644-650

  Binus, A M ^a   Han, J ^a,d   Qamar, A A ^b   Mody, E A ^c   Holt, E W ^e   Qureshi, A A ^a,d  

^a Clinical Research Program   (United States)

^b Hepatology and Endoscopy   (United States)

^c Department of Rheumatology ^*  (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; AUTOIMMUNE THYROIDITIS; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MELANOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

AGED; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PSORIASIS;

EID: 84860221763     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04153.x     Document Type: Review

References (43)

1. Naldi L,. Epidemiology of psoriasis. Curr Drug Targets 2004; 3: 121-128. (Pubitemid 38832741)
2. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005; 16: 319-323. (Pubitemid 43170202)
3. Bernstein CN, Wajda A, Blanchard JF,. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-836. (Pubitemid 41242675)
4. Lee FI, Bellary SV, Francis C,. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990; 85: 962-963. (Pubitemid 20235791)
5. Hammer B, Ashurst P, Naish J,. Diseases associated with ulcerative colitis and Crohn's disease. Gut 1968; 9: 17-21.
6. Yates VM, Watkinson G, Kelman A,. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982; 106: 323-330. (Pubitemid 12177002)
7. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997; 6: 1349-1356. (Pubitemid 27351077)
8. Najarian DJ GA,. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003; 48: 822-824.
9. Nalichowski R, Keogh D, Chueh HC, Murphy SN,. Calculating the benefits of a Research Patient Data Repository. AMIA Annu Symp Proc 2006; 2006: 1044.
10. Moll JM, Wright V,. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
11. Hauner H, Hanisch J, Bramlage P, et al. Prevalence of undiagnosed Type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Exp Clin Endocrinol Diabetes 2008; 116: 18-25. (Pubitemid 351270904)
12. Baena Diez JM, Oller Colom M, Martin Penacoba R, Nicolau Sabate M, Altes Boronat A, Iglesias Serrano C,. Impact of the new diagnostic criteria proposed by the American Diabetes Association (ADA-97) on the diagnostic prevalence of type 2 diabetes mellitus. Aten Primaria 1999; 24: 97-100.
13. Cohen R, Robinson DJ, Paramore C, Fraeman K, Renahan K, Bala M,. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis 2008; 14: 738-743. (Pubitemid 351898056)
14. Kozuch PL, Hanauer SB,. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354-377. (Pubitemid 351320845)
15. Brownstein MH,. Psoriasis and diabetes mellitus. Arch Dermatol 1966; 93: 654-655.
16. Mallbris L, Ritchlin CT, Stahle M,. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006; 8: 355-363. (Pubitemid 44638828)
17. Gibson SH, Perry HO,. Diabetes and psoriasis. A.M.A. Arch Dermatol 1956; 74: 487-488.
18. Reeds RE Jr, Fusaro RM, Fisher I,. Psoriasis vulgaris I. A clinical survey of the association with diabetes mellitus. Arch Dermatology 1964; 89: 205-208.
19. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629-634. (Pubitemid 46400186)
20. Qureshi AA, Choi HK, Setty AR, Curhan GC,. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-382.
21. Brodell RT, Williams L,. A corticosteroid-induced flare of psoriasis. How to control or, better yet, avoid. Postgrad Med 1999; 106: 31-32.
22. Garden JM, Freinkel RK,. Systemic absorption of topical steroids. Metabolic effects as an index of mild hypercortisolism. Arch Dermatol 1986; 122: 1007-1010. (Pubitemid 16053113)
23. Zaghloul SS, Goodfield MJ,. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-414. (Pubitemid 38469243)
24. Bonapace ES, Srinivasan R,. Simultaneous occurrence of inflammatory bowel disease and thyroid disease. Am J Gastroenterol 2001; 96: 1925-1926.
25. Inokuchi T, Moriwaki Y, Takahashi S, Tsutsumi Z, Ka T, Yamamoto T,. Autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in two patients with Crohn's disease: case reports and literature review. Intern Med 2005; 44: 303-306. (Pubitemid 40663031)
26. Weetman AP,. Autoimmune thyroid disease. Autoimmunity 2004; 37: 337-340. (Pubitemid 39172925)
27. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ,. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003; 139: 1425-1429. (Pubitemid 37433132)
28. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB,. The risk of lymphoma in patients with psoriasis. J Investig Dermatol 2006; 126: 2194-2201. (Pubitemid 44413165)
29. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F,. Melanomas in renal transplant recipients. Br J Dermatol 2006; 154: 472-477. (Pubitemid 43382655)
30. Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-2895. (Pubitemid 47502734)
31. Gisbert JP, Gonzalez-Lama Y, Mate J,. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 19-37. (Pubitemid 44902861)
32. Warren RB, Brown BC, Lavery D, Ashcroft DM, Griffiths CE,. Biologic therapies for psoriasis: practical experience in a UK tertiary referral centre. Br J Dermatol 2009; 160: 162-169.
33. D'Haens G,. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007; 56: 725-732. (Pubitemid 46662941)
34. Baumgart DC, Grittner U, Steingraber A, Azzaro M, Philipp S,. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis 2011; doi:. [Epub ahead of print].
35. Fiorino G, Allez M, Malesci A, Danese S,. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 921-927.
36. Gladman DD,. Psoriatic arthritis. Rheum Dis Clin North Am 1998; 24: 829-844, x. (Pubitemid 28524026)
37. Gottlieb AB, Chao C, Dann F,. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21. (Pubitemid 351252710)
38. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-330. (Pubitemid 352009830)
39. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 789-796.
40. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F,. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-928. (Pubitemid 38903524)
41. Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 1386-1394.
42. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008; 57: 1518-1523.
43. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ,. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162-169.